By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. For example, experts estimate MDMA-assisted therapy for PTSD will cost upwards of $12,000 per patient. These high costs highlight the need for comprehensive…
Lykos’ current application is based on MDMA-assisted therapy, and FDA will almost surely require that patients take the drug in a clinical setting.
A combination of high demand and a patent monopoly has created a perfect storm of profitability for Janssen’s Spravato.
Psychedelics hold promise to address an array of conditions, but potential benefits may be stratified along the lines of socioeconomic status.
While standard doses of psychedelics will ostensibly be higher than a microdose, the question of just how much higher should be the topic of debate.
A mutual understanding of the term “microdosing psychedelics” is needed to conduct accurate research, promote regulations, and educate the wider population.
